• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

针对促黄体生成激素释放激素进行主动免疫对雄激素敏感的邓宁R3327-PAP和雄激素非依赖的邓宁R3327-AT2.1前列腺癌亚系的影响。

Effect of active immunization against luteinizing hormone-releasing hormone on the androgen-sensitive Dunning R3327-PAP and androgen-independent Dunning R3327-AT2.1 prostate cancer sublines.

作者信息

Fuerst J, Fiebiger E, Jungwirth A, Mack D, Talwar P G, Frick J, Rovan E

机构信息

Department of Zoology, University of Salzburg, Austria.

出版信息

Prostate. 1997 Jul 1;32(2):77-84. doi: 10.1002/(sici)1097-0045(19970701)32:2<77::aid-pros1>3.0.co;2-c.

DOI:10.1002/(sici)1097-0045(19970701)32:2<77::aid-pros1>3.0.co;2-c
PMID:9215394
Abstract

BACKGROUND

The objective of this study was to determine the effect of active immunization against LHRH on the growth characteristics and histology of subcutaneously implanted tumors of the androgen-sensitive Dunning R3327-PAP and androgen-independent R3327-AT2.1 rat prostate adenocarcinoma sublines.

RESULTS

We herein demonstrate that 1) active immunization with an LHRH-diphtheria toxoid-conjugate (LHRH-DT) leads to the downregulation of gonadotropins and testosterone and consequently the atrophy of testosterone-dependent organs such as the testes, prostate, and androgen-sensitive Dunning R3327-PAP tumors, 2) growth inhibition of Dunning R3327-PAP tumors is caused by suppression of cell division rather than by an increase in cell death and is associated with an increase of the tumor stroma content, and 3) volume increase of the androgen-independent Dunning R3327-AT2.1 tumor is slightly but significantly reduced, indicating a local stimulatory LHRH loop within this tumor cell line.

摘要

背景

本研究的目的是确定针对促黄体生成素释放激素(LHRH)进行主动免疫对雄激素敏感的邓宁R3327-PAP和雄激素非依赖性R3327-AT2.1大鼠前列腺腺癌亚系皮下植入肿瘤的生长特性和组织学的影响。

结果

我们在此证明:1)用LHRH-白喉类毒素偶联物(LHRH-DT)进行主动免疫会导致促性腺激素和睾酮下调,从而使睾丸、前列腺和雄激素敏感的邓宁R3327-PAP肿瘤等睾酮依赖器官萎缩;2)邓宁R3327-PAP肿瘤的生长抑制是由细胞分裂受抑制引起的,而非细胞死亡增加所致,并且与肿瘤基质含量增加有关;3)雄激素非依赖性邓宁R3327-AT2.1肿瘤的体积增加略有但显著减少,表明该肿瘤细胞系内存在局部刺激性LHRH环路。

相似文献

1
Effect of active immunization against luteinizing hormone-releasing hormone on the androgen-sensitive Dunning R3327-PAP and androgen-independent Dunning R3327-AT2.1 prostate cancer sublines.针对促黄体生成激素释放激素进行主动免疫对雄激素敏感的邓宁R3327-PAP和雄激素非依赖的邓宁R3327-AT2.1前列腺癌亚系的影响。
Prostate. 1997 Jul 1;32(2):77-84. doi: 10.1002/(sici)1097-0045(19970701)32:2<77::aid-pros1>3.0.co;2-c.
2
Synthetic luteinizing hormone releasing hormone (LHRH) vaccine for effective androgen deprivation and its application to prostate cancer immunotherapy.用于有效雄激素剥夺的合成促黄体生成素释放激素(LHRH)疫苗及其在前列腺癌免疫治疗中的应用。
Vaccine. 2004 Mar 12;22(9-10):1300-13. doi: 10.1016/j.vaccine.2003.08.044.
3
Gonadotrophin releasing hormone-based vaccine, an effective candidate for prostate cancer and other hormone-sensitive neoplasms.促性腺激素释放激素疫苗,前列腺癌及其他激素敏感性肿瘤的有效候选药物。
Adv Exp Med Biol. 2008;617:581-7. doi: 10.1007/978-0-387-69080-3_60.
4
Immunotherapy of prostate cancer in a murine model using a novel GnRH based vaccine candidate.在小鼠模型中使用一种新型的基于促性腺激素释放激素(GnRH)的候选疫苗对前列腺癌进行免疫治疗。
Vaccine. 2007 Dec 5;25(50):8460-8. doi: 10.1016/j.vaccine.2007.09.033. Epub 2007 Oct 4.
5
Active immunization against LHRH alone or combined with LHRH-analogue treatment impedes growth of androgen-dependent prostatic carcinoma.单独针对促黄体生成素释放激素(LHRH)进行主动免疫或与LHRH类似物联合治疗可抑制雄激素依赖性前列腺癌的生长。
Am J Reprod Immunol. 1995 Sep;34(3):200-6. doi: 10.1111/j.1600-0897.1995.tb00939.x.
6
Expression of gonadotropin-releasing hormone receptor mRNA in the rat ventral prostate and dunning R3327 PAP adenocarcinoma before and after castration.阉割前后大鼠腹侧前列腺和邓宁R3327 PAP腺癌中促性腺激素释放激素受体mRNA的表达
Prostate. 1999 May;39(2):101-7. doi: 10.1002/(sici)1097-0045(19990501)39:2<101::aid-pros4>3.0.co;2-j.
7
Receptors for luteinizing hormone-releasing hormone (LHRH) in Dunning R3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LHRH antagonist SB-75.用促黄体激素释放激素(LHRH)拮抗剂SB - 75的持续释放系统治疗后,Dunning R3327前列腺癌和大鼠垂体前叶中促黄体激素释放激素(LHRH)的受体情况。
Endocrinology. 1990 Dec;127(6):3052-60. doi: 10.1210/endo-127-6-3052.
8
Immunization against luteinizing hormone-releasing hormone fusion proteins does not decrease prostate cancer in the transgenic adenocarcinoma mouse prostate model.在转基因腺癌小鼠前列腺模型中,针对促黄体生成素释放激素融合蛋白的免疫接种不会降低前列腺癌的发生率。
Exp Biol Med (Maywood). 2003 Jul;228(7):818-22. doi: 10.1177/15353702-0322807-07.
9
Renewal timing of long-acting depot luteinizing hormone-releasing hormone agonist (Zoladex) is critical in the treatment of hormone-dependent rat prostatic carcinoma (R3327-H).
Prostate. 1987;11(3):281-90. doi: 10.1002/pros.2990110308.
10
Differential effects of prolactin on rat dorsolateral prostate and R3327 prostatic tumor sublines.催乳素对大鼠背外侧前列腺和R3327前列腺肿瘤亚系的不同作用。
J Urol. 1985 Jun;133(6):1112-20. doi: 10.1016/s0022-5347(17)49392-x.